As global markets navigate a complex landscape of steady interest rates and fluctuating consumer confidence, Asian stock markets have shown mixed performance, with China's CSI 300 Index remaining relatively stable while Japan's indices experienced declines. In this environment, identifying undervalued stocks can be particularly appealing to investors seeking opportunities amid broader market uncertainties.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| Zhejiang Century Huatong GroupLtd (SZSE:002602) |
CN¥19.53 |
CN¥38.86 |
49.7% |
| Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) |
HK$422.80 |
HK$834.50 |
49.3% |
| Shuangdeng Group (SEHK:6960) |
HK$14.45 |
HK$28.47 |
49.3% |
| Ningxia Building Materials GroupLtd (SHSE:600449) |
CN¥13.16 |
CN¥26.20 |
49.8% |
| Morimatsu International Holdings (SEHK:2155) |
HK$10.18 |
HK$20.23 |
49.7% |
| GigaVis (KOSDAQ:A420770) |
₩57800.00 |
₩115523.82 |
50% |
| Genesem (KOSDAQ:A217190) |
₩6240.00 |
₩12405.53 |
49.7% |
| Forth Corporation (SET:FORTH) |
THB5.65 |
THB11.16 |
49.4% |
| BEAUTY GARAGE (TSE:3180) |
¥1415.00 |
¥2785.12 |
49.2% |
| Asia-potash International Investment (Guangzhou)Co.Ltd (SZSE:000893) |
CN¥54.55 |
CN¥107.83 |
49.4% |
Here we highlight a subset of our preferred stocks from the screener.
Zylox-Tonbridge Medical Technology
Overview:Zylox-Tonbridge Medical Technology Co., Ltd. is a medical device company specializing in neuro- and peripheral-vascular interventional devices, operating both in China and internationally, with a market cap of HK$8.37 billion.
Operations:The company generates revenue of CN¥898.46 million from the sale of neurovascular and peripheral-vascular interventional surgical devices.
Estimated Discount To Fair Value:22.6%
Zylox-Tonbridge Medical Technology is trading at HK$24.8, below its estimated future cash flow value of HK$32.05, suggesting it may be undervalued based on cash flows. Despite significant insider selling recently, the company forecasts robust earnings growth of 36.3% annually over the next three years, outpacing Hong Kong's market average. Recent product innovations showcased at their Investor Open Day further strengthen their competitive position in endovascular technology and support potential revenue growth beyond market expectations.
Beijing Roborock Technology
Overview:Beijing Roborock Technology Co., Ltd. specializes in the design, research and development, production, and sales of intelligent sweeping robots in China with a market cap of CN¥38.17 billion.
Operations:The company's revenue primarily comes from its Intelligent Cleaning Products segment, which generated CN¥17.00 billion.
Estimated Discount To Fair Value:31%
Beijing Roborock Technology is trading at CN¥147.32, below its estimated future cash flow value of CN¥213.48, indicating undervaluation based on cash flows. Despite a drop in profit margins from 21.7% to 9.1%, earnings are forecast to grow significantly at 30.8% annually, surpassing China's market growth rate of 28.5%. The company recently completed a share buyback worth CN¥73.87 million, reflecting strategic financial management amid its removal from an index constituent list in December 2025.
Better Life Commercial Chain ShareLtd
Overview:Better Life Commercial Chain Share Co., Ltd operates in the commercial retail sector in China with a market cap of CN¥13.98 billion.
Operations:The company's revenue primarily comes from the Wholesale and Retail Industry, amounting to CN¥2.86 billion.
Estimated Discount To Fair Value:26.3%
Better Life Commercial Chain ShareLtd is trading at CN¥5.2, below its estimated future cash flow value of CN¥7.05, highlighting undervaluation based on cash flows. Revenue is projected to grow at 31.2% annually, outpacing the Chinese market's average growth rate of 14.7%. Although Return on Equity is expected to remain low at 7.1% in three years, the company anticipates becoming profitable within that period with earnings growth forecasted at a substantial 88.75% per year.
Seize The Opportunity
-
Dive into all 248 of the Undervalued Asian Stocks Based On Cash Flows we have identified here.
-
Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
-
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Ready To Venture Into Other Investment Styles?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2190 SHSE:688169 and SZSE:002251.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
